Expert Interview
A Second Look at the Phase 1, 6-month Data from Wave Life Sciences' INLIGHT Trial Evaluating WVE-007, an Investigational siRNA therapy, in Patients with Obesity and Type 2 Diabetes
Ticker(s): WVE, LLY, NVOInstitution: Emory University
- Professor of Medicine (Endocrinology, Metabolism, and Lipids);
- Manages 30 pts per month with type 2 diabetes
- Serves as the Chief Medical Officer and Chief Quality & Patient Safety Officer for Emory Healthcare
How are you currently managing patients with obesity and type 2 diabetes, and what unmet needs remain with existing pharmacologic options?
Added By: sara_adminWhat is your interpretation of the interim Phase 1 INLIGHT data for WVE-007, particularly the observed reductions in visceral fat and preservation of lean mass?
Added By: sara_adminWhich patient populations (e.g., degree of obesity, metabolic profile, comorbidities) do you believe may benefit most from a therapy like WVE-007?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
